BCR
$249.91
C.R. Bard
$1.18
.47%
BCR
Earnings Whisper ®
N/A
1st Quarter March 2017
Consensus:  $2.65
Revenue:  $925.18 Mil
Thursday
Apr 27
4:15 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Thursday, January 26, 2017

What do you expect when BCR reports earnings?
Beat
Meet
Miss

Where is BCR's stock price going from here?
Up
Flat
Down
Stock chart of BCR
Analysts
Summary of analysts' recommendations for BCR
Score
Grade
Pivots
Resistance
$252.41
$251.53
$250.72

$249.84

Support
$249.03
$248.15
$247.34
Tweet
Growth
Description
C.R. Bard, Inc. is one of the worldwide leaders in developing, manufacturing, and supplying healthcare products that focus on Vascular, Urology, and Oncology Disease States. In addition, Bard offers a complete line of advanced Surgical Specialty products and services that address needs in hernia repair, performance irrigation, hemostasis, and other areas.
Peers
StrykerBoston ScientificAbbott LaboratoriesIntegra LifeSciences HoldingsWatersBecton, DickinsonBaxter International3MResMedHaemonetics